Assenagon Asset Management Acquires Stake in Soleno Therapeutics

The institutional investor purchased over 384,000 shares of the biotech company in Q4 2025.

Mar. 27, 2026 at 7:22am

Got story updates? Submit your updates here. ›

Assenagon Asset Management S.A. acquired a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the fourth quarter of 2025, according to the company's recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 384,166 shares of the company's stock, valued at approximately $17.79 million, representing approximately 0.72% ownership of Soleno Therapeutics.

Why it matters

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases. The acquisition of a significant stake by Assenagon Asset Management, a major institutional investor, signals potential confidence in the company's pipeline and future prospects.

The details

Assenagon Asset Management S.A. purchased the 384,166 shares of Soleno Therapeutics in the fourth quarter of 2025. This represents the firm's first investment in the company. Soleno Therapeutics is currently developing its lead candidate, diazoxide choline controlled release (DCCR), for the treatment of Prader-Willi syndrome, a rare genetic disorder characterized by insatiable appetite, hormonal imbalances, and behavioral challenges.

  • Assenagon Asset Management S.A. acquired the Soleno Therapeutics shares in the fourth quarter of 2025.
  • Soleno Therapeutics is currently developing its lead candidate DCCR for the treatment of Prader-Willi syndrome.

The players

Assenagon Asset Management S.A.

An institutional investment management firm that acquired a new position in Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, including its lead candidate DCCR for the treatment of Prader-Willi syndrome.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of a significant stake in Soleno Therapeutics by a major institutional investor like Assenagon Asset Management suggests potential confidence in the company's pipeline and future prospects, particularly its lead candidate DCCR for the treatment of the rare genetic disorder Prader-Willi syndrome.